If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
However, temperatures at Plateau Station were only recorded during the 37 months that it was active. Had a lower temperature than the Vostok record occurred there at a later date, it would never have been recorded. Monitoring stations in Antarctica are few and far between; prior to 1995, Vostok was the only research station on the Antarctic Plateau above the elevation of 3,000 m (with the exception of Plateau Station during the brief period that it was active in the 1960s), with no other stations for several hundred kilometers in any direction. Temperatures below −89.2 °C (−128.6 °F), if they did occur elsewhere, would not have been recorded. The automatic weather station at Dome A was only installed in 2005, and has recorded −82.5 °C (−116.5 °F) as the coldest so far (2010). However, a review of satellite measurements taken between 2010 and 2013 found several places located along a ridge between Dome A and Dome F which recorded even lower temperatures of −92 to −94 °C (−134 to −137 °F), with the lowest reliable temperature being −93.2 °C (−135.8 °F) recorded in 2010, at 81°48′S 59°18′E, at an elevation of 3,900 m (12,800 ft). The extreme low temperatures are found in hollows slightly below the peak of the ice ridge, where cold air gets trapped as it flows downhill, and since the same low temperature ranges were detected at several different sites along the ridge across multiple years, it is thought this may be the lowest temperature achievable under local atmospheric conditions.
== Biochemical function == Glutathione exists in reduced (GSH) and oxidized (GSSG) states. The ratio of reduced glutathione to oxidized glutathione within cells is a measure of cellular oxidative stress where increased GSSG-to-GSH ratio is indicative of greater oxidative stress. In the reduced state, the thiol group of cysteinyl residue is a source of one reducing equivalent. Glutathione disulfide (GSSG) is thereby generated. The oxidized state is converted to the reduced state by NADPH. This conversion is catalyzed by glutathione reductase:
== Prevention == Moderate-quality evidence exists that suggests that the combination of education and exercise may reduce an individual's risk of developing an episode of low back pain. Lesser-quality evidence points to exercise alone as a possible deterrent to the risk of the condition.
Charge-exchange ionization (also known as charge-transfer ionization) is a gas phase reaction between an ion and an atom or molecule in which the charge of the ion is transferred to the neutral species.
Sources: en.wikipedia.org
=== Cancer === Abdominal obesity has been associated with an increased risk of several cancers, particularly malignancies of the digestive system. These include colorectal, pancreatic, and esophageal cancers. These associations often remain even after adjustment for overall body mass index, which suggests that abdominal fat distribution is an independent risk factor. In women, abdominal obesity has also been linked to higher rates of breast cancer in both the pre- and post-menopausal periods, beyond the effects of general obesity.
=== Linker === Between the reactive group and the tag, ABPs often include a linker / spacer / biorecognition element, which can tune probe solubility, steric accessibility, and substrate mimicry. Simple linkers may consist of alkyl chains or polyethylene glycol (PEG) spacers which adjust hydrophobicity and improve labeling across diverse proteomes. More complex designs incorporate biorecognition elements which can impart enzyme family or subfamily selectivity. For example, substrate-mimetic phosphonates have been used to target specific serine proteases and optimized peptide sequences can discriminate caspase isoforms. Binding or targeting motifs within the linker can further enhance interactions with enzymes whose active sites impose structural constraints, thereby improving probe specificity. In addition, linker length and composition can modulate probe permeability and distribution in cellular or in vivo contexts. This component allows probe designers to balance breadth (profiling an entire enzyme class) versus specificity (targeting individual members).
In 1958, Korolev upgraded the R-7 to be able to launch a 400-kilogram (880 lb) payload to the Moon. The Luna program began with three failed secret 1958 attempts to launch Luna E-1-class impactor probes. The fourth attempt, Luna 1, launched successfully on January 2, 1959, but missed the Moon. The fifth attempt on June 18 also failed at launch. The 390-kilogram (860 lb) Luna 2 successfully impacted the Moon on September 14, 1959. The 278.5-kilogram (614 lb) Luna 3 successfully flew by the Moon and sent back pictures of its far side on October 7, 1959. The US first embarked on the Pioneer program in 1958 by launching the first probe, albeit ending in failure. A subsequent probe named Pioneer 1 was launched with the intention of orbiting the Moon only to result in a partial mission success when it reached an apogee of 113,800 km before falling back to Earth. The missions of Pioneer 2 and Pioneer 3 failed whereas Pioneer 4 had one partially successful lunar flyby in March 1959.
Pakistan is considered a middle power nation, with the world's seventh-largest standing armed forces in terms of personnel size, comprising approximately 660,000 active-duty troops and 291,000 paramilitary personnel as of 2024. Established in 1947, the armed forces of Pakistan wielded significant influence over national politics. The main branches include the Army, Navy, and Air Force, supported by numerous paramilitaries. The Chairman of the Joint Chiefs of Staff Committee (CJCSC) is the highest-ranking military officer, advising the civilian government. However, they lack direct command over the branches and serve as intermediaries, ensuring communication between the military and civilian leadership. Overseeing the Joint Staff Headquarters, they coordinate inter-service cooperation and joint military missions. Command and control over Pakistan's strategic arsenal development and employment is vested in the National Command Authority, overseeing work on nuclear doctrine to maintain Full spectrum deterrence. The United States, Turkey, and China maintain close military relations with Pakistan Armed Forces, regularly exporting military equipment and technology transfer. Pakistan was the 5th-largest recipient and importer of arms between 2019 and 2023.
It has since been elucidated that androgens like testosterone and dihydrotestosterone (DHT) function as trophic factors for the prostate gland, stimulating cell division and proliferation and producing tissue growth and glandular enlargement, which, in the context of prostate cancer, results in stimulation of tumors and a considerable acceleration of disease progression. As a result of these discoveries, androgen deprivation therapy (ADT), via a variety of modalities including surgical castration, high-dose estrogens, SAAs, GnRH analogues, NSAAs, and androgen biosynthesis inhibitors (e.g., abiraterone acetate), has become the mainstay of treatment for prostate cancer. Although ADT can shrink or stabilize prostate tumors and hence significantly slow the course of prostate cancer and prolong life, it is not generally curative. While effective in slowing the progression of the disease initially, most advanced prostate cancer patients eventually become resistant to ADT and prostate cancer growth starts to accelerate again, in part due to progressive mutations in the androgen receptor (AR) that result in the transformation of drugs like bicalutamide from AR antagonists to agonists. A few observations form the basis of the reasoning behind combined androgen blockade (CAB), in which castration and an NSAA are combined. It has been found that very low levels of androgens, as in castration, are able to significantly stimulate growth of prostate cancer cells and accelerate disease progression.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.